Cytosorbents Corporation
CTSO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $35,595 | $31,085 | $34,689 | $40,109 |
| % Growth | 14.5% | -10.4% | -13.5% | – |
| Cost of Goods Sold | $10,469 | $9,132 | $13,956 | $11,047 |
| Gross Profit | $25,126 | $21,953 | $20,733 | $29,061 |
| % Margin | 70.6% | 70.6% | 59.8% | 72.5% |
| R&D Expenses | $6,916 | $15,594 | $15,119 | $16,381 |
| G&A Expenses | $0 | $37,872 | $2,212 | $38,482 |
| SG&A Expenses | $0 | $38,307 | $2,794 | $38,482 |
| Sales & Mktg Exp. | $0 | $435 | $582 | $0 |
| Other Operating Expenses | $34,996 | $0 | $34,342 | -$3,057 |
| Operating Expenses | $41,912 | $53,902 | $52,255 | $51,806 |
| Operating Income | -$16,786 | -$31,949 | -$31,522 | -$22,745 |
| % Margin | -47.2% | -102.8% | -90.9% | -56.7% |
| Other Income/Exp. Net | -$5,624 | $1,888 | -$2,383 | -$2,550 |
| Pre-Tax Income | -$22,410 | -$30,060 | -$33,905 | -$25,295 |
| Tax Expense | -$1,691 | -$814 | -$1,093 | -$736 |
| Net Income | -$20,719 | -$29,247 | -$32,813 | -$24,559 |
| % Margin | -58.2% | -94.1% | -94.6% | -61.2% |
| EPS | -0.38 | -0.65 | -0.75 | -0.57 |
| % Growth | 41.5% | 13.3% | -31.6% | – |
| EPS Diluted | -0.38 | -0.65 | -0.75 | -0.57 |
| Weighted Avg Shares Out | 54,435 | 44,656 | 43,573 | 43,359 |
| Weighted Avg Shares Out Dil | 54,435 | 44,656 | 43,573 | 43,359 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $133 | $28 |
| Interest Expense | $1,399 | $158 | $0 | $0 |
| Depreciation & Amortization | $1,570 | $2,023 | $883 | $1,130 |
| EBITDA | -$15,216 | -$27,879 | -$30,003 | -$21,615 |
| % Margin | -42.7% | -89.7% | -86.5% | -53.9% |